EIDD-2801
| CAS No. | 2349386-89-4 | Cat. No. | BCP32744 |
| Name | EIDD-2801 | ||
| Synonyms | EIDD 2801; EIDD2801; Molnupiravir; MK-4482; MK4482; MK 4482; prodrug-EIDD-1931; prodrug-EIDD 1931; prodrug-EIDD1931; | ||
| Formula | C13H19N3O7 | M. Wt | 329.31 |
| Description | EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. | ||
| Pathways | Microbiology/Virology | ||
| Targets | Influenza Virus SARS CoV | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.